News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Immunomedics, Inc. (IMMU) Develops Bispecific Hexavalent Antibodies for Diverse Epithelial Cancers



4/3/2012 9:54:53 AM

CHICAGO, April 2, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the development of two bispecific, hexavalent antibodies for treating breast, pancreatic and other solid cancers.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES